Carbonyl–heterobimetallic Ru(II)/Fe(II)–complexes containing polypyridyl ligands: Synthesis, characterization, cellular viability assays and interactions with biomolecules

Dávila-Rodriguez, María-José; Barolli, João P.; Oliveira, Katia M.; Colina‐Vegas, Legna; Miranda, Fabio da Silva; Castellano, Eduardo E.; Poelhsitz, Gustavo Von; Batista, Alzir A.

doi:10.1016/j.abb.2018.10.020

Cited by 11 publications

(9 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Those results represented the first evidence of an in vivo effect of FcOHTam and ferrocenyl derivatives on xenografted breast tumors [35]. For many years, and more recently, the interaction between a variety of transition metals with polypyridyl ligands and DNA has been extensively studied as part of the efforts to fight cancer [36][37][38][39][40][41][42][43][44][45]. Due to unusual binding properties and general photoactivity, these coordination compounds are suitable candidates as DNA secondary structure probes, photocleaving agents, and anti-cancer drugs [46].…”

Section: Introductionmentioning

confidence: 85%

“…and ctDNA binding studies-The investigation of the binding of metal complexes to DNA is of prime importance in the development of anticancer drugs [196]. From a pharmacological point of view, the primary target of many anticancer drugs is DNA [36][37][38][39][40][41][42][43][44][45]. Consequently, DNA binding activities of metal complexes have often been a key parameter during the development of chemotherapeutic drugs.…”

Section: Spectroscopic Studies In Water Pbs Buffer and An Aqueous Smentioning

confidence: 99%

See 1 more Smart Citation

Synthesis, characterization, DNA binding, topoisomerase inhibition, and apoptosis induction studies of a novel cobalt(III) complex with a thiosemicarbazone ligand

Beebe¹,

Celestine

Bullock

et al. 2020

Journal of Inorganic Biochemistry

View full text Add to dashboard Cite

× 10 5 and 1.6 × 10 4 M −1 , respectively). Topoisomerase inhibition assays and cleavage studies proved that complex 4 was an efficient catalytic inhibitor of human topoisomerases I and IIα. Based upon the results obtained from the 3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay on 4T1-luc metastatic mammary breast cancer cells (IC 50 = 34.4 ± 5.2 μM when compared to IC 50 = 13.75 ± 1.08 μM for the control, cisplatin), further investigations into the molecular events initiated by exposure to complex 4 were investigated. Studies have shown that complex 4 activated both the apoptotic and autophagic signaling pathways in addition to causing dissipation of the mitochondrial membrane potential (ΔΨ m). Furthermore, activation of cysteine-aspartic proteases3 (caspase 3) in a time-and concentration-dependent manner coupled with the ΔΨ m , studies implicated the intrinsic apoptotic pathway as the major regulator of cell death mechanism.

show abstract

Section: Introductionmentioning

confidence: 85%

Section: Spectroscopic Studies In Water Pbs Buffer and An Aqueous Smentioning

confidence: 99%

Synthesis, characterization, DNA binding, topoisomerase inhibition, and apoptosis induction studies of a novel cobalt(III) complex with a thiosemicarbazone ligand

Beebe¹,

Celestine

Bullock

et al. 2020

Journal of Inorganic Biochemistry

View full text Add to dashboard Cite

show abstract

“…DNA binding studies with calf thymus DNA suggested non‐classical or electrostatic interactions. There was also no correlation observed for the extension of the polypyridyl ligands and the cytotoxicity observed …”

Section: Rutheniummentioning

confidence: 92%

“…The Ru‐Fe complexes investigated by Chakraborty and colleagues ( 74 – 85 ), Costa et al ( 86 ) and Batista and colleagues ( 87 – 90 ). The IC 50 (µM) values reported are shown below the chemical structures.…”

Section: Rutheniummentioning

confidence: 99%

See 1 more Smart Citation

Heterometallic Multinuclear Complexes as Anti‐Cancer Agents‐An Overview of Recent Developments

2019

View full text Add to dashboard Cite

This review provides a critical assessment of the advances made in the development of heterometallic multinuclear complexes as potential chemotherapeutic agents, with the aim of providing a starting point for future investigators. The combination of the classical transition metals (Pt, Ru and Au) with other metal moieties has the potential to result in complexes with improved pharmacokinetic and pharmacodynamic properties. This enables selective targeting of the bio- [a] 3434 Figure 2. The Pt II -Ru III complexes, IT127 and AH-197, [35] and the macrocyclic rectangles investigated by Chi and colleagues. [36] The IC 50 (μM) values reported are shown below the chemical structures.

show abstract

Heterometallic Ferrocenyl Complexes and Their Application in the Treatment of Cancer

Lord¹,

Hofmann²,

Stringer³

2022

Encyclopedia of Inorganic and Bioinorganic Chemistry

View full text Add to dashboard Cite

Ferrocene, a stable 18‐electron metallocene, has been readily modified to include other functionalities by reactions such as Friedel–Crafts and Mannich. While ferrocene and its derivatives have many applications, for example, as fuel additives and materials chemistry, they have been heavily researched in the past three decades for their medicinal applications; namely, tamoxifen, a well‐known breast cancer drug, has been modified with ferrocene (ferrocifen) to improve breast cancer selectivity, and chloroquine, an antimalarial drug, was modified with ferrocene to improve its activity in chloroquine‐resistant malarial strains. In these two molecules, ferrocene imparts a metal‐specific effect, enhancing the therapeutic potential of these complexes. Ferrocifen and ferroquine are currently in phase II clinical trials and preclinical evaluation, respectively. No other ferrocene‐containing complexes have reached clinical trial stages. One strategy that could fast‐track these complexes to an advanced stage is to develop heterometallic complexes, as they often exhibit enhanced pharmacological properties and have different biological targets compared to their homometallic/mononuclear counterparts. In this article, we have highlighted the area of heterometallic ferrocenyl complexes and their applications in the treatment of cancer and look at the most promising complexes to date.

show abstract

Carbonyl–heterobimetallic Ru(II)/Fe(II)–complexes containing polypyridyl ligands: Synthesis, characterization, cellular viability assays and interactions with biomolecules

Cited by 11 publications

References 102 publications

Synthesis, characterization, DNA binding, topoisomerase inhibition, and apoptosis induction studies of a novel cobalt(III) complex with a thiosemicarbazone ligand

Synthesis, characterization, DNA binding, topoisomerase inhibition, and apoptosis induction studies of a novel cobalt(III) complex with a thiosemicarbazone ligand

Heterometallic Multinuclear Complexes as Anti‐Cancer Agents‐An Overview of Recent Developments

Heterometallic Ferrocenyl Complexes and Their Application in the Treatment of Cancer

Contact Info

Product

Resources

About